• Joel Wight, Nada Hamad, Belinda A Campbell, Matthew Ku, Kenneth Lee, Hannah Rose, Tasman Armytage, Maya Latimer, Hui-Peng Lee, Sze-Ting Lee, Michael Dickinson, Richard Khor, and Emma Verner.
• Department of Haematology and Bone Marrow Transplantation, Townsville University Hospital, Townsville, Queensland, Australia.
• Intern Med J. 2022 Sep 1; 52 (9): 1609-1623.

AbstractDiffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.© 2021 Royal Australasian College of Physicians.

15 keywords...

hide…